Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Department of Nursing, Mackay Medical College, New Taipei City, Taiwan
  2. Department of Community Psychiatry, Bali Psychiatric Center, MOHW, New Taipei City, Taiwan
  3. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
  4. Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan
  5. Corresponding author: Yu-Hsuan Joni Shao, PhD, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 172-1 Keelung Rd, Section 2, Taipei 106, Taiwan ([email protected]).
  1. Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–333. PubMed CrossRef
  2. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224. PubMed CrossRef
  3. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. PubMed CrossRef
  4. Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. PubMed CrossRef
  5. Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. PubMed CrossRef
  6. Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. PubMed CrossRef
  7. Sacchetti E, Grunze H, Leucht S, et al. Long-acting injection antipsychotic medications in the management of schizophrenia. Evidence-Based Psychiatr Care. 2015;1:27–36.
  8. Horvitz‐Lennon M, Predmore Z, Orr P, et al. Simulated long‐term outcomes of early use of long‐acting injectable antipsychotics in early schizophrenia. Early Interv Psychiatry. 2019;13(6):1357–1365. PubMed
  9. Parellada E, Velligan DI, Emsley R, et al. Long-acting injectable antipsychotics in first-episode schizophrenia. Schizophr Res Treatment. 2012;2012:318535. PubMed CrossRef
  10. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210–213. PubMed CrossRef
  11. Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. PubMed CrossRef
  12. Huang C-Y, Fang S-C, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021;4(5):e218810–e218810. PubMed CrossRef
  13. Harvey PD, Loewenstein DA, Czaja SJ. Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiol Dis. 2013;53:18–25. PubMed CrossRef
  14. Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459–468. PubMed CrossRef
  15. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med. 2008;148(4):258–267. PubMed CrossRef
  16. Lu T-H, Lee M-C, Chou M-C. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol. 2000;29(2):336–343. PubMed CrossRef
  17. Ritchie CW, Harrigan S, Mastwyk M, et al. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. Int J Geriatr Psychiatry. 2010;25(4):411–418. PubMed CrossRef
  18. World Health Organization. ATC/DDD Index. 2014.
  19. Karson C, Duffy RA, Eramo A, et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:57–67. PubMed CrossRef
  20. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692–699. PubMed CrossRef
  21. Jespersen CG, Nørgaard M, Bjerklund Johansen TE, et al. The influence of cardiovascular morbidity on the prognosis in prostate cancer: experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer. 2011;11(1):519. PubMed CrossRef
  22. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. PubMed CrossRef
  23. Taipale H, Mehtälä J, Tanskanen A, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387. PubMed CrossRef
  24. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry suppl. 1998;172(S33):53–59. PubMed CrossRef
  25. Munday J, Greene M, Chang E, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin. 2019;35(7):1231–1239. PubMed CrossRef
  26. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–663. PubMed CrossRef
  27. Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619. PubMed
  28. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83–92. PubMed CrossRef
  29. Anderson KK, Voineskos A, Mulsant BH, et al. The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanisms of neurotoxicity in first-episode psychosis. Can J Psychiatry. 2014;59(10):513–517. PubMed CrossRef
  30. Ortiz BB, Eden FDM, de Souza ASR, et al. New evidence in support of staging approaches in schizophrenia: differences in clinical profiles between first episode, early stage, and late stage. Compr Psychiatry. 2017;73:93–96. PubMed CrossRef
  31. Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry. 2006;67(10):e14. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe